Imbria Pharmaceuticals is focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction
Imbria Pharmaceuticals is focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction.